Who and Where
Who is looking at NAC in COVID?
Determination of efficacy of N-Acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease
CHA-IRB-1139-05/20
ClinicalTrials.gov ID NCT04419025
Phase
Application submission to CHA IRB May 1, 2020
Approval August 7, 2020
Enrollment September 30, 2020
Principal Investigator (PI)
Melisa Lai-Becker MD
Enrollment Eligibility (updated 12/8/2020)
Age >= 18 years, not pregnant at time of enrollment; known or suspect COVID-19 disease AND one or more of any influenza-like symptom, including:
diarrhea
vomiting
fever (subjective or measured)
chills
myalgias
fatigue
sore throat
headache
cough
nasal/sinus congestion or rhinorrhea
shortness of breath
chest pain
John Adams MD MPH Internist and Pediatrician, CHA Acute Care/Respiratory Clinic project leader; Instructor, Harvard Medical School
Kerry Blomquist RN Emergency Nurse, CHA Everett Hospital
Pieter Cohen MD Internist, Primary Care, CHA; Associate Professor, Harvard Medical School
Julie Devito PA-C Physician Assistant, CHA Department of Emergency Medicine
Jessica Early MD Family Medicine Physician, Hospitalist, CHA; Assistant Professor, Tufts University School of Medicine
Ellie Grossman MD MPH Primary Care Lead for Behavioral Health Integration; Instructor, Harvard Medical School
Lara Hall MD Family Medicine Physician; CHA Acute Care/Respiratory Clinic COVID-19 Clinical Lead
Rachel Hathaway MD Hospital Medicine Physician. Director, HMS Medicine Sub Internship; Director, CHA Internal Medicine Resident Evaluation; Instructor, Harvard Medical School
Janice N. John PA-C MHS MHCDS Medical Director, CHA Acute Care/Respiratory Clinic; Chief PA, Primary Care; Associate Medical Director, Assembly Square Primary Care
Duncan Kuhn MD Pulmonary & Critical Care Physician, CHA; Pulmonary & Critical Care Physician, North Shore Medical Center (Salem MA); Infectious Diseases specialist; Instructor, Harvard Medical School
Melisa Lai-Becker MD Chief, Everett Emergency Department; Director, Division of Medical Toxicology; Medical Toxicologist, Regional Center for Poison Control and Prevention Serving MA & RI; Medical Toxicologist, Boston Children's Hospital; Assistant Professor, Harvard Medical School
Anna Rabkina MD Internist, Primary Care, CHA and Lynn Community Health Center; Team Leader, Market Square Family Health Services; Instructor, Harvard Medical School
Mary Regan PharmD Director, Clinical and Academic Pharmacy Services; Senior Clinical Pharmacist Specialist – Critical Care; Administrator, ACPE-Accredited CPE Programming
Neha Sandeep PA-C Family Medicine PA, CHA Acute Care/Respiratory Clinic and Primary Care, CHA
Yamini Saravanan MD MHS Clerkship Director, HMS Primary Care; Clerkship Director, HMS Internal Medicine Clerkship; Associate Director, HMS Primary Care Experience; Instructor, Harvard Medical School
Alix Schrager MD Senior resident (PGY3), Harvard Internal Medicine Residency at CHA; Clinical Fellow in Medicine, Harvard Medical School
Anna Shapiro PA-C Physician Assistant, CHA Primary Care
Linda Shipton MD Infectious Diseases specialist, CHA and Spaulding Rehabilitation Center; Medical Director, Tuberculosis Program, MA DPH, CHA; Assistant Professor, Harvard Medical School
Tom Seufert MD Emergency Physician; Associate Director of Clinical Informatics; Director of Emergency Informatics; Instructor, Harvard Medical School
Lisa Yasi RRT Respiratory Therapist, CHA Everett
Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19
ClinicalTrials.gov Identifier: NCT04545008
Prisma Health and Clemson University
A Study of N-acetylcysteine in Patients With COVID-19 Infection
ClinicalTrials.gov Identifier: NCT04374461
Memorial Sloan Kettering Cancer Center
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients (PRANA)
ClinicalTrials.gov Identifier: NCT04458298
Ashvattha Therapeutics (formerly Orpheris, Inc.)
Inflammatory Regulation Effect of NAC on COVID-19 Treatment (INFECT-19)
ClinicalTrials.gov Identifier: NCT04455243
King Saud University, Saudi Arabia
Clinical Application of Methylene Blue for Treatment of Covid-19 Patients (Covid-19)
ClinicalTrials.gov Identifier: NCT04370288
Mashhad University of Medical Sciences, Iran
Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu
ClinicalTrials.gov Identifier: NCT04279197
ShuGuang Hospital, Shanghai, China
Antioxidant Therapy for COVID-19 Study (GSHSOD-COVID)
ClinicalTrials.gov Identifier: NCT04466657
Obafemi Awolowo University, Nigeria